Who is sponsoring NCT05145751?

NCT05145751 is sponsored by University of Thessaly.

What drugs are being tested in NCT05145751?

Interventions in NCT05145751: Simple inflammatory biomarkers measurement.

What condition does NCT05145751 study?

NCT05145751 studies COVID-19, Inflammation.

Is NCT05145751 still recruiting?

NCT05145751 is currently completed. Last updated 2 March 2022.

Last reviewed 2022-03-02 · How we verify

NCT05145751

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SARS CoV-2 Infection and Inflammatory Biomarkers

Completed Last updated 2 March 2022

What this trial tests

trial testing Simple inflammatory biomarkers measurement in COVID-19 in 115 participants. Completed in 31 January 2022.

Timeline

1 April 2021

Primary endpoint
1 October 2021

31 January 2022

Quick facts

Lead sponsor	University of Thessaly
Status	Completed
Study type	OBSERVATIONAL
Enrollment	115
Start date	1 April 2021
Primary completion	1 October 2021
Estimated completion	31 January 2022
Sites	1 location across Greece

Drugs / interventions tested

Simple inflammatory biomarkers measurement

Conditions studied

COVID-19 — all drugs for COVID-19 →
Inflammation — all drugs for Inflammation →

Sponsor

University of Thessaly

Who can join

18 and older, any sex, with COVID-19 or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Early research suggests that inflammation plays a key role in the development of SARS CoV-2 infection. The immune response to respiratory infection is characterized by an influx of neutrophils to the lungs. This study ought to investigate the association of simple biomarkers such as NLR and PLR with the clinical outcome in SARS CoV-2 infection patients.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Predicting the Outcome of Patients with Severe COVID-19 with Simple Inflammatory Biomarkers: The Utility of Novel Combined Scores-Results from a European Tertiary/Referral Centre.
Ntalouka MP, Brotis A, Mermiri M, Pagonis A, et al · · 2024 · cited 8× · PMID 38398280 · DOI 10.3390/jcm13040967
Prognostic role of simple inflammatory biomarkers in patients with severe COVID-19: an observational study.
Ntalouka MP, Pantazopoulos I, Brotis AG, Pagonis A, et al · · 2022 · cited 2× · PMID 37188050

Verify or expand the search:

Other recruiting trials for COVID-19

Currently open trials in the same condition.

NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting

Other University of Thessaly trials

Trials by the same sponsor.

NCT07376187 — Digital Physiotherapy for Pediatric Chronic Suppurative Lung Diseases · NA · not yet recruiting
NCT07496151 — The Effectiveness of Neurodevelopmental Treatment (Bobath) and Functional Physiotherapy in Children With Cerebral Palsy. · NA · not yet recruiting
NCT07420309 — Colonoscopy TRaining With or Without Artificial INtelligence Among Endoscopy Residents · NA · recruiting
NCT07341711 — Long-term Adaptations of Skeletal Muscle After Hybrid Training. · NA · not yet recruiting
NCT07380009 — Acceptability and Adherence to Different Dosing Regimens of the Multistrain Probiotic Vivomixx® 460 Neo 9 in Adults Rece · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05145751 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Thessaly
Last refreshed: 2 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05145751.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing